Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 19/20 | 1.00 |
| ▸ | FNTB | P49356 | 17/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.71 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8750304 | 0.91 | FNTA (1.00) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL14175665 | 0.86 | FNTA (0.84) | FNTAFNTBTDP1PGGT1BKMT2A | |
| SCHEMBL8365606 | 0.83 | FNTA (1.00) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL8586036 | 0.83 | FNTA (1.00) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL6056511 | 0.83 | FNTA (1.00) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL29381983 | 0.83 | FNTA (1.00) | FNTAFNTBTDP1PGGT1B | |
| Hydrochloric Acid SCHEMBL8492799 | 0.82 | FNTA (0.98) | FNTAFNTBTDP1PGGT1B | |
| Hydrochloric Acid SCHEMBL8492805 | 0.82 | FNTA (0.98) | FNTAFNTBTDP1PGGT1B | |
| Hydrochloric Acid SCHEMBL29686212 | 0.82 | FNTA (0.98) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL8495155 | 0.81 | FNTA (0.69) | FNTAFNTBTDP1PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658277-A1 | METHODS OF TREATING VIRAL INFECTION | Griffith University (AU) | 2025-12-10 | — | — | EP | disclosed |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| WO-2024159259-A1 | METHODS OF TREATING VIRAL INFECTION | GRIFFITH UNIVERSITY (AU) | 2024-08-08 | — | — | WO | disclosed |
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3166607-B1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | FNTA 3930/4885FNTB 2672/4885TDP1 2254/4885 |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | FNTA 3930/4885FNTB 2672/4885TDP1 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.